Published in Heart Fail Rev on July 01, 2015
Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med (2008) 9.40
Long-term comparison of endovascular and open repair of abdominal aortic aneurysm. N Engl J Med (2012) 4.62
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol (2002) 3.97
Cell therapy for cardiac repair--lessons from clinical trials. Nat Rev Cardiol (2014) 3.57
Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 3.56
Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. JAMA (2007) 3.09
Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials. Lancet (1988) 2.84
Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet (2007) 2.48
Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov (2012) 2.33
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J (2011) 2.32
Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model. Circulation (2007) 2.24
The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol (2014) 1.99
Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myocardial infarction: the AMISTAD-2 trial. Eur Heart J (2006) 1.86
The intrinsic prostaglandin E2-EP4 system of the renal tubular epithelium limits the development of tubulointerstitial fibrosis in mice. Kidney Int (2012) 1.66
Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: the STATIN STEMI trial. JACC Cardiovasc Interv (2010) 1.65
Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol (2010) 1.59
Reverse remodeling in heart failure--mechanisms and therapeutic opportunities. Nat Rev Cardiol (2011) 1.49
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circ J (2013) 1.39
Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation (2004) 1.36
Injectable acellular hydrogels for cardiac repair. J Cardiovasc Transl Res (2011) 1.19
Gene therapy to treat cardiovascular disease. J Am Heart Assoc (2013) 1.13
Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol (2012) 1.13
Preconditioning with sevoflurane decreases PECAM-1 expression and improves one-year cardiovascular outcome in coronary artery bypass graft surgery. Br J Anaesth (2004) 1.05
Impaired myocardium regeneration with skeletal cell sheets--a preclinical trial for tissue-engineered regeneration therapy. Transplantation (2010) 1.04
The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure. Clin Sci (Lond) (2014) 1.03
Beneficial effects of the CorCap cardiac support device: five-year results from the Acorn Trial. J Thorac Cardiovasc Surg (2011) 1.02
Effect of a selective agonist for prostaglandin E receptor subtype EP4 (ONO-4819) on the cortical bone response to mechanical loading. Bone (2005) 1.02
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets. Nat Rev Cardiol (2014) 1.02
Role of arachidonic acid lipoxygenase metabolites in the regulation of vascular tone. Am J Physiol Heart Circ Physiol (2009) 1.01
Pharmacological activation of the prostaglandin E2 receptor EP4 improves cardiac function after myocardial ischaemia/reperfusion injury. Cardiovasc Res (2008) 1.00
Coronary microvascular dysfunction: mechanisms and functional assessment. Nat Rev Cardiol (2014) 0.97
The mechanism of anti-inflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation (2009) 0.97
Current clinical management of pulmonary arterial hypertension. Circ Res (2014) 0.96
Targeting the renin-angiotensin-aldosterone system in heart failure. Nat Rev Cardiol (2013) 0.95
A role for pericytes in coronary no-reflow. Nat Rev Cardiol (2014) 0.94
PGI2 as a regulator of inflammatory diseases. Mediators Inflamm (2012) 0.94
Remifentanil reduces the release of biochemical markers of myocardial damage after coronary artery bypass surgery: a randomized trial. J Cardiothorac Vasc Anesth (2010) 0.94
Pharmacologic therapy that simulates conditioning for cardiac ischemic/reperfusion injury. J Cardiovasc Pharmacol Ther (2013) 0.93
Prostacyclin agonist with thromboxane synthase inhibitory activity (ONO-1301) attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol (2005) 0.92
Unique regulation profile of prostaglandin e1 on adhesion molecule expression and cytokine production in human peripheral blood mononuclear cells. J Pharmacol Exp Ther (2003) 0.91
Transcatheter aortic valve replacement: current perspectives and future implications. Heart (2014) 0.91
Novel regenerative therapy using cell-sheet covered with omentum flap delivers a huge number of cells in a porcine myocardial infarction model. J Thorac Cardiovasc Surg (2011) 0.90
A novel strategy for myocardial protection by combined antibody therapy inhibiting both P-selectin and intercellular adhesion molecule-1 via retrograde intracoronary route. Circulation (2006) 0.90
Effects on improvement of blood flow in the chronically compressed cauda equina: comparison between a selective prostaglandin E receptor (EP4) agonist and a prostaglandin E1 derivate. Spine (Phila Pa 1976) (2006) 0.88
Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial. Inflamm Bowel Dis (2010) 0.88
Prostacyclin therapy for pulmonary arterial hypertension. Tex Heart Inst J (2010) 0.88
Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol (2014) 0.87
Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am J Respir Crit Care Med (2007) 0.87
The anti-inflammatory effect of bradykinin preconditioning in coronary artery bypass grafting (bradykinin and preconditioning). Scand Cardiovasc J (2009) 0.85
Sustained-release prostacyclin analog ONO-1301 ameliorates tubulointerstitial alterations in a mouse obstructive nephropathy model. Am J Physiol Renal Physiol (2012) 0.84
Prostaglandin EP4 receptor agonist augments fixation of hydroxyapatite-coated implants in a rat model of osteoporosis. J Bone Joint Surg Br (2005) 0.84
Prostaglandin E2 EP4 agonist (ONO-4819) accelerates BMP-induced osteoblastic differentiation. Bone (2007) 0.84
Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats. Bone (2006) 0.83
Devices in the management of advanced, chronic heart failure. Nat Rev Cardiol (2012) 0.83
Prostaglandin D2 and prostaglandin E2 accelerate the recovery of cutaneous barrier disruption induced by mechanical scratching in mice. Eur J Pharmacol (2005) 0.83
Enhanced efficiency of superoxide dismutase-induced cardioprotection by retrograde intracoronary administration. Cardiovasc Res (2005) 0.83
Endovascular healing is inadequate for fixation of Dacron stent-grafts in human aortoiliac vessels. Eur J Vasc Endovasc Surg (2000) 0.82
Single injection of ONO-1301-loaded PLGA microspheres directly after ischaemia reduces ischaemic damage in rats subjected to middle cerebral artery occlusion. J Pharm Pharmacol (2011) 0.82
Prostaglandin E2 EP4 receptor-selective agonist facilitates sternal healing after harvesting bilateral internal thoracic arteries in diabetic rats. J Thorac Cardiovasc Surg (2006) 0.81
Enhancing effects of a prostaglandin EP4 receptor agonist on recombinant human bone morphogenetic protein-2 mediated spine fusion in a rabbit model. Spine (Phila Pa 1976) (2007) 0.81
Cell-sheet therapy with omentopexy promotes arteriogenesis and improves coronary circulation physiology in failing heart. Mol Ther (2014) 0.81
A prostanoid receptor EP4 agonist enhances ectopic bone formation induced by recombinant human bone morphogenetic protein-2. Biochem Biophys Res Commun (2004) 0.81
Sustained-release delivery of prostacyclin analogue enhances bone marrow-cell recruitment and yields functional benefits for acute myocardial infarction in mice. PLoS One (2013) 0.81
Differential effect of prostaglandins E1 and E2 on lipopolysaccharide-induced adhesion molecule expression on human monocytes. Eur J Pharmacol (2005) 0.81
Quantitative assessment of initial retention of bone marrow mononuclear cells injected into the coronary arteries. J Heart Lung Transplant (2010) 0.80
A synthetic small molecule, ONO-1301, enhances endogenous growth factor expression and augments angiogenesis in the ischaemic heart. Clin Sci (Lond) (2007) 0.80
A long-acting prostacyclin agonist with thromboxane inhibitory activity for pulmonary hypertension. Am J Respir Crit Care Med (2005) 0.80
Choice of cell-delivery route for successful cell transplantation therapy for the heart. Future Cardiol (2013) 0.80
Synthetic prostacycline agonist, ONO-1301, ameliorates left ventricular dysfunction and cardiac fibrosis in cardiomyopathic hamsters. Biomed Pharmacother (2009) 0.79
Intermittent administration of a sustained-release prostacyclin analog ONO-1301 ameliorates renal alterations in a rat type 1 diabetes model. Prostaglandins Leukot Essent Fatty Acids (2010) 0.79
Impact of cardiac support device combined with slow-release prostacyclin agonist in a canine ischemic cardiomyopathy model. J Thorac Cardiovasc Surg (2013) 0.79
Effect of prostaglandin I2 analogs on macrophage inflammatory protein 1α in human monocytes via I prostanoid receptor and cyclic adenosine monophosphate. J Investig Med (2014) 0.78
Synthetic prostacyclin agonist, ONO1301, enhances endogenous myocardial repair in a hamster model of dilated cardiomyopathy: a promising regenerative therapy for the failing heart. J Thorac Cardiovasc Surg (2013) 0.78
Stimulation of EP4 receptor enhanced bone consolidation during distraction osteogenesis. J Orthop Res (2007) 0.78
Pharmacological therapy for myocardial reperfusion injury. Curr Opin Pharmacol (2004) 0.78
Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol (2010) 0.77
Suppression of fibrogenic gene expression and liver fibrosis using a synthetic prostacyclin agonist. Biomed Res (2013) 0.77
The anti-inflammatory mechanism of prostaglandin e2 receptor 4 activation in rat experimental autoimmune myocarditis. J Cardiovasc Pharmacol (2011) 0.77
A slow-releasing form of prostacyclin agonist (ONO1301SR) enhances endogenous secretion of multiple cardiotherapeutic cytokines and improves cardiac function in a rapid-pacing-induced model of canine heart failure. J Thorac Cardiovasc Surg (2013) 0.77
A sustained prostacyclin analog, ONO-1301, attenuates pancreatic fibrosis in experimental chronic pancreatitis induced by dibutyltin dichloride in rats. Pancreatology (2014) 0.76
Prostaglandins E1 and E2 inhibit lipopolysaccharide-induced interleukin-18 production in monocytes. Eur J Pharmacol (2005) 0.76
Prostaglandin E(2) receptors as potential bone anabolic targets - selective EP4 receptor agonists. Curr Mol Pharmacol (2012) 0.76
A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res (2001) 0.76
A prostacycline analog prevents chronic myocardial remodeling in murine cardiac allografts. Int Heart J (2012) 0.76
Suppression of acute hepatic injury by a synthetic prostacyclin agonist through hepatocyte growth factor expression. Am J Physiol Gastrointest Liver Physiol (2011) 0.76
A single injection of a sustained-release prostacyclin analog (ONO-1301MS) suppresses airway inflammation and remodeling in a chronic house dust mite-induced asthma model. Eur J Pharmacol (2013) 0.76
Novel long-acting prostacyclin agonist (ONO-1301) with an angiogenic effect: promoting synthesis of hepatocyte growth factor and increasing cyclic AMP concentration via IP-receptor signaling. J Pharmacol Sci (2013) 0.76
A synthetic prostacyclin agonist with thromboxane synthase inhibitory activity, ONO-1301, protects myocardium from ischemia/reperfusion injury. Eur J Pharmacol (2011) 0.76
Heart failure in 2013: Continue what we are doing to treat HF, but do it better. Nat Rev Cardiol (2013) 0.76
Non-prostanoid prostacyclin agonists for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs (2006) 0.76
Kinetic study of the hepatobiliary transport of a new prostaglandin receptor agonist. J Pharmacol Exp Ther (1998) 0.76
Cardioprotection for percutaneous coronary intervention--reperfusion quality as well as quantity. Int J Cardiol (2014) 0.76
A prostacyclin agonist with thromboxane inhibitory activity for airway allergic inflammation in mice. Clin Exp Allergy (2009) 0.76
Beneficial effect of a synthetic prostacyclin agonist, ONO-1301, in rat autoimmune myocarditis model. Eur J Pharmacol (2012) 0.76
Effect of antioxidants on the stability of ONO-1301, a novel long-acting prostacyclin agonist, loaded in PLGA microspheres. J Microencapsul (2012) 0.75
Local delivery of synthetic prostacycline agonist augments collateral growth and improves cardiac function in a swine chronic cardiac ischemia model. Life Sci (2009) 0.75
Modulation of anti-glomerular basement membrane nephritis in rats by ONO-1301, a non-prostanoid prostaglandin I2 mimetic compound with inhibitory activity against thromboxane A2 synthase. Jpn J Pharmacol (1997) 0.75
The effect of treatment with a sustained-release prostacyclin analogue (ONO-1301-loaded PLGA microsphere) on short-term memory impairment in rats with transient global cerebral ischemia. J Microencapsul (2012) 0.75
Long-term outcomes after a variety of video-assisted thoracoscopic lobectomy approaches for clinical stage IA lung cancer: a multi-institutional study. J Thorac Cardiovasc Surg (2006) 2.23
Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model. Circulation (2012) 1.98
Risk factor analysis of long-term support with left ventricular assist system. Circ J (2010) 1.87
Repair of impaired myocardium by means of implantation of engineered autologous myoblast sheets. J Thorac Cardiovasc Surg (2005) 1.82
Late complications of gelatin-resorcin-formalin glue in the repair of acute type A aortic dissection. Ann Thorac Surg (2007) 1.75
Oxidized low-density lipoproteins trigger endoplasmic reticulum stress in vascular cells: prevention by oxygen-regulated protein 150 expression. Circ Res (2008) 1.56
In vivo differentiation of induced pluripotent stem cell-derived cardiomyocytes. Circ J (2013) 1.55
Novel method of decellularization of porcine valves using polyethylene glycol and gamma irradiation. Ann Thorac Surg (2007) 1.55
Endovascular aortic repair increases vascular stiffness and alters cardiac structure and function. Circ J (2013) 1.49
Coronary artery bypass grafting in hemodialysis-dependent patients: analysis of Japan Adult Cardiovascular Surgery Database. Circ J (2012) 1.49
Novel tissue-engineered biodegradable material for reconstruction of vascular wall. Ann Thorac Surg (2005) 1.46
Alterations in the medial layer of the main pulmonary artery in a patient with longstanding Fontan circulation. Interact Cardiovasc Thorac Surg (2010) 1.46
Fibronectin-hepatocyte growth factor enhances reendothelialization in tissue-engineered heart valve. Ann Thorac Surg (2005) 1.46
Long-term results of hybrid endovascular repair for thoraco-abdominal aortic aneurysms. Eur J Cardiothorac Surg (2010) 1.46
Predictor of early mortality for severe heart failure patients with left ventricular assist device implantation: significance of INTERMACS level and renal function. Circ J (2012) 1.45
Early experiences of transcatheter aortic valve replacement in Japan. Circ J (2012) 1.44
Coronary microcirculatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. Ann Thorac Surg (2009) 1.44
Virtual mediastinoscopy for safer and more accurate mediastinal exploration. Ann Thorac Surg (2007) 1.44
Tissue engineered myoblast sheets improved cardiac function sufficiently to discontinue LVAS in a patient with DCM: report of a case. Surg Today (2011) 1.44
Prevalence and optimal management strategy for aortic regurgitation in tetralogy of Fallot. Eur J Cardiothorac Surg (2004) 1.43
Early Outcomes in Japanese Dialysis Patients Treated With Transcatheter Aortic Valve Implantation. Circ J (2015) 1.42
Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun (2008) 1.42
Arch aneurysm repair with long elephant trunk: a 10-year experience in 111 patients. Ann Thorac Surg (2009) 1.41
Aortic remodeling as a prognostic factor for late aortic events after thoracic endovascular aortic repair in type B aortic dissection with patent false lumen. J Endovasc Ther (2014) 1.41
Restrictive mitral annuloplasty for functional mitral regurgitation: acute hemodynamics and serial echocardiography. Circ J (2010) 1.39
Oral administration of a novel long-acting prostacyclin agonist with thromboxane synthase inhibitory activity for pulmonary arterial hypertension. Circ J (2013) 1.39
Human cardiac stem cells with reduced notch signaling show enhanced therapeutic potential in a rat acute infarction model. Circ J (2013) 1.39
Single-stage repair of arch aneurysms with a long elephant trunk: medium-term follow-up of thromboexcluded aneurysms. J Thorac Cardiovasc Surg (2007) 1.38
Design of prevascularized three-dimensional cell-dense tissues using a cell sheet stacking manipulation technology. Biomaterials (2009) 1.35
Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol (2007) 1.35
Initial experience of conversion of Toyobo paracorporeal left ventricular assist device to DuraHeart left ventricular assist device. Circ J (2011) 1.34
Who would be a candidate for bridge to recovery during prolonged mechanical left ventricular support in idiopathic dilated cardiomyopathy? J Thorac Cardiovasc Surg (2005) 1.33
Bioengineered myocardium derived from induced pluripotent stem cells improves cardiac function and attenuates cardiac remodeling following chronic myocardial infarction in rats. Stem Cells Transl Med (2012) 1.30
Tissue cardiomyoplasty using bioengineered contractile cardiomyocyte sheets to repair damaged myocardium: their integration with recipient myocardium. Transplantation (2005) 1.30
Recovery of right heart function with temporary right ventricular assist using a centrifugal pump in patients with severe biventricular failure. J Heart Lung Transplant (2012) 1.29
Enhanced survival of transplanted human induced pluripotent stem cell-derived cardiomyocytes by the combination of cell sheets with the pedicled omental flap technique in a porcine heart. Circulation (2013) 1.28
Fifteen-year experience with Toyobo paracorporeal left ventricular assist system. J Artif Organs (2009) 1.28
Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. Int J Cardiol (2010) 1.25
Circulating tumor cells in peripheral blood caused by surgical manipulation of non-small-cell lung cancer: pilot study using an immunocytology method. Gen Thorac Cardiovasc Surg (2007) 1.21
BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene (2003) 1.19
Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. Cardiovasc Res (2006) 1.19
Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension (2004) 1.19
Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc (2012) 1.18
Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model. J Thorac Cardiovasc Surg (2006) 1.17
Developments for a growing Japanese patient population: facilitating new technologies for future health care. J Proteomics (2010) 1.15
Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Circulation (2010) 1.15
Heat shock protein 72 enhances manganese superoxide dismutase activity during myocardial ischemia-reperfusion injury, associated with mitochondrial protection and apoptosis reduction. Circulation (2002) 1.15
CD34+ cells represent highly functional endothelial progenitor cells in murine bone marrow. PLoS One (2011) 1.15
Long-term results of the open stent-grafting technique for extended aortic arch disease. J Thorac Cardiovasc Surg (2008) 1.14
DuraHeart™ magnetically levitated left ventricular assist device: Osaka University experience. Circ J (2013) 1.11
A novel sphingosine 1-phosphate receptor agonist, 2-amino-2-propanediol hydrochloride (KRP-203), regulates chronic colitis in interleukin-10 gene-deficient mice. J Pharmacol Exp Ther (2007) 1.11
Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation (2002) 1.10
Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg (2002) 1.10
HDL/apolipoprotein A-I binds to macrophage-derived progranulin and suppresses its conversion into proinflammatory granulins. J Atheroscler Thromb (2010) 1.09
Mycotic aneurysm of the infrarenal abdominal aorta infected by Clostridium septicum: a case report of surgical management and review of the literature. J Vasc Surg (2003) 1.09
Therapeutic strategy for treating aortoesophageal fistulas. Gen Thorac Cardiovasc Surg (2014) 1.08
Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol Heart Circ Physiol (2005) 1.06
Amelioration of pulmonary emphysema by in vivo gene transfection with hepatocyte growth factor in rats. Circulation (2005) 1.06
HIV mucosal vaccine: nasal immunization with gp160-encapsulated hemagglutinating virus of Japan-liposome induces antigen-specific CTLs and neutralizing antibody responses. J Immunol (2003) 1.06
Layered implantation of myoblast sheets attenuates adverse cardiac remodeling of the infarcted heart. J Thorac Cardiovasc Surg (2009) 1.06
Lung tissue engineering technique with adipose stromal cells improves surgical outcome for pulmonary emphysema. Am J Respir Crit Care Med (2006) 1.05
Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol (2010) 1.05
Tissue-engineered cardiac constructs for cardiac repair. Ann Thorac Surg (2011) 1.04
Hepatocyte growth factor suppresses vascular medial hyperplasia and matrix accumulation in advanced pulmonary hypertension of rats. Circulation (2004) 1.04
Immunological function of thymoma and pathogenesis of paraneoplastic myasthenia gravis. Gen Thorac Cardiovasc Surg (2008) 1.04
An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol (2007) 1.04
Impaired myocardium regeneration with skeletal cell sheets--a preclinical trial for tissue-engineered regeneration therapy. Transplantation (2010) 1.04
Clinical and pathological aspects of thymic epithelial tumors. Gen Thorac Cardiovasc Surg (2008) 1.04
Clinical report of long-term support with dual Jarvik 2000 biventricular assist device. J Heart Lung Transplant (2011) 1.03
Properties of hepatocyte-like cell clusters from human adipose tissue-derived mesenchymal stem cells. Tissue Eng Part C Methods (2010) 1.03
Safety and Efficacy of Autologous Skeletal Myoblast Sheets (TCD-51073) for the Treatment of Severe Chronic Heart Failure Due to Ischemic Heart Disease. Circ J (2015) 1.02
The use of cell-sheet technique eliminates arrhythmogenicity of skeletal myoblast-based therapy to the heart with enhanced therapeutic effects. Int J Cardiol (2012) 1.01
Skeletal myoblast sheet transplantation improves the diastolic function of a pressure-overloaded right heart. J Thorac Cardiovasc Surg (2009) 1.01
Myocardial recovery by mechanical unloading with left ventricular assist system. Circ J (2009) 1.00
Transdifferentiation of human adipose tissue-derived stromal cells into insulin-producing clusters. J Artif Organs (2009) 1.00
Initial report of bridge to recovery in a patient with DuraHeart LVAD. J Artif Organs (2013) 0.99
Unusual thrombus formation in the aorta after apicoaortic conduit for severe aortic stenosis. J Thorac Cardiovasc Surg (2006) 0.97
Prognosis of smokers following resection of pathological stage I non-small-cell lung carcinoma. Gen Thorac Cardiovasc Surg (2007) 0.97
Hybrid endovascular aortic arch repair using branched endoprosthesis: the second-generation "branched" open stent-grafting technique. J Thorac Cardiovasc Surg (2009) 0.97